Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355575 | 0.93 | TSHR (0.41) | TSHRNFKB1CYP2C19KDM5AKDM4C | |
| SCHEMBL4020424 | 0.84 | ALDH1A1 (0.37) | TSHRNFKB1CYP2C19KDM5AKDM4C | |
| SCHEMBL22287128 | 0.83 | — | — | |
| SCHEMBL18711702 | 0.82 | TSHR (0.35) | TSHRNFKB1CYP2C19KDM5AKDM4C | |
| SCHEMBL10590189 | 0.80 | TSHR (0.34) | TSHRNFKB1CYP2C19KDM5AKDM4C | |
| SCHEMBL378129 | 0.80 | TSHR (0.34) | TSHRNFKB1CYP2C19KDM5AKDM4C | |
| SCHEMBL20707613 | 0.80 | ALDH1A1 (0.34) | TSHRNFKB1CYP2C19ALDH1A1KMT2A | |
| SCHEMBL2004049 | 0.78 | MEN1 (0.33) | FFAR3ALDH1A1KMT2AMEN1 | |
| SCHEMBL17157143 | 0.78 | FFAR3 (0.36) | FFAR3 | |
| SCHEMBL12499298 | 0.78 | ALDH1A1 (0.35) | TSHRNFKB1CYP2C19KDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115246787-A | Meta-disubstituted compound, preparation thereof and application thereof in preventing and treating mosquito and plant pathogenic bacteria | 吉林省达凯生物医药有限公司 | 2022-10-28 | — | — | CN | claimed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4539841-A2 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| CN-118974020-A | Substituted 3-aminoindazole derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024175024-A1 | NEW FUSED HETEROCYCLIC COMPOUND AS CDKS INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-4359404-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Celgene Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-115246787-B | Meta-disubstituted compound, preparation thereof and application thereof in preventing and treating mosquito and plant pathogen diseases | 吉林省达凯生物医药有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-2906537-A2 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2015-08-19 | — | — | EP | disclosed |
| CN-102670605-B | Suppress the kinase whose method of C KIT | JANSSEN PHARMACEUTICA N. V. (BE) | 2015-07-29 | — | — | CN | disclosed |
| EP-2834248-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2015-02-11 | — | — | EP | disclosed |
| WO-2014062733-A2 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2013150036-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2013-10-10 | — | — | WO | disclosed |
| CN-102670605-A | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV | 2012-09-19 | — | — | CN | disclosed |
| CN-101437514-B | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV | 2012-04-25 | — | — | CN | disclosed |
| CN-101610768-B | Methods of inhibiting C KIT kinase | JANSSEN PHARMACEUTICA NV | 2012-03-21 | — | — | CN | disclosed |
| CN-101610768-A | Methods of inhibiting C KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-23 | — | — | CN | disclosed |
| CN-101437514-A | Inhibidores of C-FMS cinasa | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | TSHR 3800/4885NFKB1 3572/4885CYP2C19 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.